Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN)

Q: What does CUSIP 92840H400 represent in this 13F holders report?

CUSIP 92840H400 is the security identifier for VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2025?

53 institutional investors reported VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 92840H400

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 39,040,476
Total 13F shares: 13,134,779
Share change: -7,609,434
Total reported value: $8,693,359
Put/Call ratio: 72%
Price per share: $0.66
Number of holders: 53
Value change: -$30,764,910
Number of buys: 31
Number of sells: 29

Quarterly Holders Quick Answers

What is CUSIP 92840H400?
CUSIP 92840H400 identifies VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 92840H400:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Venrock Healthcare Capital Partners II, L.P.	3/4/5	10%+ Owner	— class O/S missing	20,637,286	$35,434,220	—	12 Jul 2022	3/4/5
JANUS HENDERSON GROUP PLC	13F	Company	11%	4,165,767	$14,746,815	—	30 Sep 2025	13F
ORBIMED ADVISORS LLC	13F 13D/G	Company · ORBIMED CAPITAL LLC	4.2% from 13D/G	3,060,000	$10,863,000	—	30 Sep 2025	13F 13D/G
TCG Crossover Management, LLC	13F	Company	6.9%	2,676,580	$9,501,859	—	30 Sep 2025	13F
STEMPOINT CAPITAL LP	13F 13D/G	Company	1.5% from 13D/G	2,488,685	$7,749,263	—	30 Sep 2025	13F 13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	3,084,324	$7,217,318	$0	31 Dec 2024	13D/G
Nantahala Capital Management, LLC	13F 13D/G	Company	4.7% from 13D/G	1,978,492	$7,023,647	—	30 Sep 2025	13F 13D/G
VANGUARD GROUP INC	13F 13D/G	Company · The Vanguard Group	4.6% from 13D/G	1,687,735	$5,991,460	—	30 Sep 2025	13F 13D/G
Commodore Capital LP	13F 13D/G 3/4/5	Company · 10%+ Owner	9.9% from 13D/G	1,575,000	$5,591,250	—	30 Sep 2025	13F 13D/G 3/4/5
Ikarian Capital, LLC	13F	Company	1.6%	620,869	$2,204,084	—	30 Sep 2025	13F
Soleus Capital Management, L.P.	13F	Company	1.4%	550,000	$1,952,500	—	30 Sep 2025	13F
GREAT POINT PARTNERS LLC	13D/G	—	5%	2,055,834	$1,521,317	$0	31 Dec 2025	13D/G
BlackRock, Inc.	13F	Company	1.1%	423,128	$1,502,105	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.1%	422,012	$1,498,143	—	30 Sep 2025	13F
DIADEMA PARTNERS LP	13F	Company	0.9%	349,789	$1,241,751	—	30 Sep 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.78%	302,683	$1,074,525	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.76%	298,280	$1,059,256	—	30 Sep 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.74%	289,409	$1,027,402	—	30 Sep 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.7%	271,825	$964,979	—	30 Sep 2025	13F
Almitas Capital LLC	13F	Company	0.67%	261,399	$927,966	—	30 Sep 2025	13F
AdvisorShares Investments LLC	13F	Company	0.53%	206,998	$734,843	—	30 Sep 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.5%	197,024	$699,435	—	30 Sep 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.4%	157,032	$557,464	—	30 Sep 2025	13F
BML Capital Management, LLC	13F	Company	0.38%	150,000	$532,500	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.31%	122,062	$433,320	—	30 Sep 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.29%	113,062	$401,370	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.25%	96,858	$343,846	—	30 Sep 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.22%	85,594	$303,859	—	30 Sep 2025	13F
Persistent Asset Partners Ltd	13F	Company	0.19%	75,319	$267,382	—	30 Sep 2025	13F
XTX Topco Ltd	13F	Company	0.18%	69,712	$247,478	—	30 Sep 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.17%	68,017	$241,397	—	30 Sep 2025	13F
Walleye Capital LLC	13F	Company	0.17%	67,770	$240,584	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.15%	60,152	$213,540	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.12%	48,093	$170,730	—	30 Sep 2025	13F
H. Ralph Snodgrass	3/4/5	PRES./CHIEF SCIENTIFIC OFFICER	— class O/S missing	98,859	$169,741	—	31 Dec 2021	3/4/5
Cubist Systematic Strategies, LLC	13F	Company	0.11%	43,953	$156,033	—	30 Sep 2025	13F
OCCUDO QUANTITATIVE STRATEGIES LP	13F	Company	0.11%	42,704	$151,599	—	30 Sep 2025	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.11%	41,072	$145,806	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.09%	34,657	$123,032	—	30 Sep 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.08%	31,486	$112,000	—	30 Sep 2025	13F
GROUP ONE TRADING LLC	13F	Company	0.07%	28,928	$102,694	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.07%	27,534	$97,746	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.07%	25,667	$91,118	—	30 Sep 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.06%	23,302	$82,722	—	30 Sep 2025	13F
HighTower Advisors, LLC	13F	Company	0.05%	20,828	$73,939	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.05%	20,676	$73,400	—	30 Sep 2025	13F
Kestra Advisory Services, LLC	13F	Company	0.05%	20,033	$71,117	—	30 Sep 2025	13F
Quadrature Capital Ltd	13F	Company	0.04%	15,752	$55,762	—	30 Sep 2025	13F
BLAIR WILLIAM & CO/IL	13F	Company	0.03%	12,573	$44,634	—	30 Sep 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.03%	10,883	$38,633	—	30 Sep 2025	13F

Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) as of Q4 2025

As of 31 Dec 2025, Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) was held by 53 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,134,779 shares. The largest 10 holders included ORBIMED ADVISORS LLC, TCG Crossover Management, LLC, VANGUARD GROUP INC, ADAR1 Capital Management, LLC, JANE STREET GROUP, LLC, Ikarian Capital, LLC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, LUMINUS MANAGEMENT LLC, and SUSQUEHANNA INTERNATIONAL GROUP, LLP. This page lists 53 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

-5

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.